An exclusive option agreement gives one company the right to negotiate a full license for a technology before any competing party can step in. That is the structure 60 Degrees Pharmaceuticals (Nasdaq: SXTP) has reached with Florida State University, centered on a compound called castanospermine and its potential against tick-borne diseases. The arrangement extends the company's infectious disease pipeline into a therapeutic area it had not previously claimed.
What the option agreement actually covers
An option is a reserved position, not a purchase. The party holding it has paid for the right to pursue a full development license, but the research and intellectual property stay with the originating institution until a complete agreement is struck. Under this structure, Florida State University retains the underlying work on castanospermine. 60 Degrees Pharmaceuticals holds the exclusive right to be the one party that can advance it.
Exclusivity matters here. Without it, another company could approach Florida State University and negotiate its own deal on the same compound. The exclusive option blocks that path.
The compound and the disease category
Castanospermine is the compound at the center of this agreement. The source positions it for development against tick-borne diseases, a category of infections transmitted to humans or animals through tick bites. The category spans conditions caused by bacteria, viruses, and parasites carried by ticks.
How this fits the company's announced strategy
Pipeline, in pharmaceutical terms, refers to all drug candidates a company is developing before any reach the commercial market. 60 Degrees Pharmaceuticals, listed on Nasdaq under the ticker SXTP, describes the castanospermine option as an expansion of its infectious disease pipeline. That framing places tick-borne disease alongside whatever programs the company was already running.
What was signed versus what is only projected
The source confirms the exclusive option agreement and nothing more. No financial terms appear. No development timelines are given. No preclinical or clinical data on castanospermine's performance against tick-borne pathogens is cited.
An option gives the holder the right to move forward. It does not guarantee a drug candidate survives development, reaches a regulatory filing, or attracts further investment. The compound remains held at Florida State University.